Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pharmacokinetics in the child

W R Crom1

  • 1Pharmaceutical Department, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.

Environmental Health Perspectives
|December 1, 1994
PubMed
Summary
This summary is machine-generated.

Pharmacokinetic studies improve pediatric drug therapy by revealing age-specific differences in drug processing. This research informs tailored dosing guidelines and optimizes anticancer drug exposure in children.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Treatment of childhood acute myelogenous leukemia with an intensive regimen (AML-87) that individualizes etoposide and cytarabine dosages: short- and long-term effects.

Leukemia·2000
Same author

Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia.

The New England journal of medicine·1998
Same author

Probenecid alters topotecan systemic and renal disposition by inhibiting renal tubular secretion.

The Journal of pharmacology and experimental therapeutics·1998
Same author

A phase II trial of high-dose methotrexate in previously untreated children and adolescents with high-risk unresectable or metastatic rhabdomyosarcoma.

Journal of pediatric hematology/oncology·1997
Same author

Disposition of irinotecan and SN-38 following oral and intravenous irinotecan dosing in mice.

Cancer chemotherapy and pharmacology·1997
Same author

Hepatic drug clearance in patients with mild cystic fibrosis.

Clinical pharmacology and therapeutics·1996
Same journal

A New Start.

Environmental health perspectives·2026
Same journal

Time-Varying Exposure to Element Mixtures and Children's Cognition at 5 Years of Age: Findings from the New Hampshire Birth Cohort Study.

Environmental health perspectives·2026
Same journal

Effect of Household Air Pollution on the Gut Microbiome and Virome of Adult Women Living in Uganda.

Environmental health perspectives·2026
Same journal

Comparison of Temperature-Mortality Associations across the Middle East Using Different Exposure Estimation Approaches.

Environmental health perspectives·2026
Same journal

Workflow for Statistical Analysis of Environmental Mixtures.

Environmental health perspectives·2026
Same journal

Effects of Extreme Heat Exposure on Heatstroke and Liver Injury in Mice: The Role of PPARα.

Environmental health perspectives·2026
See all related articles

Area of Science:

  • Pharmacology
  • Pediatric Therapeutics
  • Drug Metabolism

Background:

  • Pharmacokinetic (PK) studies are crucial for rational drug use in children.
  • PK data highlight differences in drug disposition and sensitivity between pediatric and adult populations.
  • These differences necessitate age-specific dosage guidelines for safe and effective treatment.

Purpose of the Study:

  • To review factors influencing pharmacokinetic variability in children compared to adults.
  • To present specific applications of PK data in pediatric oncology.
  • To explore the use of PK data in defining optimal drug exposure and understanding genetic influences on drug metabolism.

Main Methods:

  • Review of factors affecting drug disposition in pediatric populations.

Related Experiment Videos

  • Utilization of model substrates to assess hepatic drug metabolism and renal excretion in children.
  • Analysis of genetic polymorphic drug metabolism and its impact on individual phenotypes.
  • Application of PK data to determine maximum-tolerated systemic exposure for anticancer drugs.

    • Main Results:

    • Pharmacokinetic data have successfully guided the establishment of age-specific drug dosage guidelines for children.
    • Studies using model substrates provide insights into hepatic and renal drug handling in pediatric patients.
    • Genetic polymorphisms in drug metabolism significantly influence individual drug responses.
    • Defining maximum-tolerated systemic exposure offers a more precise approach to anticancer drug dosing in children.

    Conclusions:

    • Pharmacokinetic studies are indispensable for optimizing therapeutic strategies in pediatric patients.
    • Understanding age-related and genetic factors in drug metabolism is key to personalized pediatric pharmacotherapy.
    • The shift towards defining maximum-tolerated systemic exposure enhances the safety and efficacy of anticancer treatments in children.